Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross Profit | $3,534.2M | $4,646.6M | $4,899.8M | $5,887.2M | $6,993.1M | $7,591.8M | $8,723.4M | $10.0B | $11.1B | $12.3B | $13.2B | $13.6B | $14.1B | $14.3B | $14.9B | $15.3B | $16.2B | $18.6B | $21.0B | $28.5B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Novo Nordisk A/S's last 12-month Gross Profit is $33.3B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Novo Nordisk A/S's Gross Profit growth was 28.8%. The average annual Gross Profit growth rates for Novo Nordisk A/S have been 26.3% over the past three years, 17.1% over the past five years.